Does impeachment have a pharma angle? Who’s to blame for drug shortages? And why is Wall Street down on biotech?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT Washington correspondent Nicholas Florko joins us to break down what the impeachment inquiry means for the congressional fight over drug prices and the fate of the FDA. Then, Dr. Ben Davies, a University of Pittsburgh urologist, calls in to discuss what happens when key drugs face dangerous shortages. Later, we dig into biotech’s rough third quarter and discuss how things might change before the year’s out. Finally, Davies sticks around for a lightning round, covering rosé, menswear, and mail-order erectile dysfunction pills.
For more on what we talk about, here’s the latest on drug pricing legislation; here’s the news on the possible next FDA commissioner; here’s more on drug shortages; and here’s a preview of the coming quarter in biotech.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email email@example.com.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at firstname.lastname@example.org.